Cancer Immunology Research · 2014 · 69 citations · 23 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyImmune Checkpoint InhibitorsMyeloid-derived Suppressor CellsT Cell Responses To TumorsTumor Immune MicroenvironmentCd8 Positive T CellsImmunosuppressive FunctionMelanoma ImmunotherapyMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell-mediated SuppressionTumor Growth DynamicsTumor Microenvironment EffectsTumor Suppression Mechanisms
A growing body of evidence suggests that BRAF inhibitors, in addition to their acute tumor growth-inhibitory effects, can also promote immune responses to melanoma. The present study aimed to define the immunologic basis of BRAF-inhibitor therapy using the Braf/Pten model of inducible, autochthonous melanoma on a pure C57BL/6 background. In the tumor microenvironment, BRAF inhibitor PLX4720 functioned by on-target mechanisms to selectively decrease both the proportions and absolute numbers of CD4(+)Foxp3(+) regulatory T cells (Treg) and CD11b(+)Gr1(+) myeloid-derived suppressor cells (MDSC), while preserving numbers of CD8(+) effector T cells. In PLX4720-treated mice, the intratumoral Treg populations decreased significantly, demonstrating enhanced apopotosis. CD11b(+) myeloid cells from PLX4720-treated tumors also exhibited decreased immunosuppressive function on a per-cell basis. In accordance with a reversion of tumor immune suppression, tumors that had been treated with PLX4720 grew with reduced kinetics after treatment was discontinued, and this growth delay was dependent on CD8 T cells. These findings demonstrate that BRAF inhibition selectively reverses two major mechanisms of immunosuppression in melanoma and liberates host-adaptive antitumor immunity.
23
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort, David P. Curley, Robert A Cartlidge et al. · Nature Genetics · 2009 · 1.2K citations · Full text
Medicine, Cancer Biology, Oncology +12
Dennie T. Frederick, Adriano Piris, Alexandria P. Cogdill et al. · Clinical Cancer Research · 2013 · 938 citations · Full text
Life Sciences, Immunology, Oncology +17